Elkhova, S. S., Filatova, L. V., Zyuzgin, I. S., Volchyonkov, S. A., Ishmatova, I. V., Zverkova, A. A., Nikulina, Y. A., Kramynin, L. A., Dobrovolskaya, E. V., & Semiglazova, T. Y. (2024). Comparison of Stem Cell Mobilization Efficacy with Intermediate Dose Cytarabine Versus Cyclophosphamide or Plerixafor in Poor Mobilizers. Voprosy Onkologii, 70(4), 727–732. https://doi.org/10.37469/0507-3758-2024-70-4-727-732

Abstract

Introduction. Insufficient stem cell mobilization is a challenge in planning autologous bone marrow transplantation. There is still no optimal approach for poor mobilizers. Recent studies demonstrate high efficacy of intermediate dose cytarabine as stem cell mobilization regimen.

Aim. To compare the efficacy of mobilization with an intermediate dose of cytarabine + G-CSF with the existing mobilization regimens: cyclophosphamide + G-CSF and the combination of plerixafor + G-CSF.

Materials and methods. We retrospectively analyzed the mobilization results of 85 patients classified as predicted poor mobilisers. Of these patients, 28 were mobilized with cytarabine + G-CSF, 28 with cyclophosphamide + G-CSF and 29 with plerixafor + G-CSF.

Results. The median number of collected CD34+ cells was 10,2 × 106/kg in cytarabine group, 7,2 × 106/kg in cyclophosphamide group and 2,5 × 106/kg in plerixafor group (р < 0,0001). The maximum number of circulating CD34+ cells was 153/ml in cytarabine group, 129/ml in cyclophosphamide group and 33/ml in plerixafor group (р = 0,005).

Conclusion. These results demonstrate high efficacy of intermediate dose cytarabine as stem cell mobilization regimen. This approach may be the treatment of choice in stem cell mobilization for predicted poor mobilizers.

https://doi.org/10.37469/0507-3758-2024-70-4-727-732

##article.numberofdownloads## 61

##article.numberofviews## 164

pdf (Русский)

References

Mohty M., Hübel K., Kröger N., et al. Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2014; 49: 865-872.-DOI: https://doi.org/10.1038/bmt.2014.39.

Giralt S., Costa L., Schriber J., et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant. 2014; 20: 295-308.-DOI: https://doi.org/10.1016/j.bbmt.2013.10.013.

Olivieri A., Marchetti M., Lemoli R., et al. Proposed definition of ‘poor mobilizer’ in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo. Bone Marrow Transplant. 2012; 47: 342-351.-DOI: https://doi.org/10.1038/bmt.2011.82.

Jelinek T., Adamusova L., Popkova T., et al. Cytarabine + G-CSF is more effective than cyclophosphamide + G-CSF as a stem cell mobilization regimen in multiple myeloma. Bone Marrow Transplant. 2019; 54(7): 1107-1114.-DOI: https://doi.org/10.1038/s41409-018-0396-x.

Bogucka-Fedorczuk A., Czyz A., Kalicińska E., et al. Higher efficacy of intermediate dose cytarabine + G-CSF compared to cyclophosphamide + G-CSF in hematopoietic stem cell mobilization in patients with multiple myeloma. J Clin Apher. 2020; 35(4): 246-254.-DOI: https://doi.org/10.1002/jca.21784.

Callera A., Rosa E., Callera F. Intermediate-dose cytarabine plus G-CSF as mobilization regimen for newly diagnosed multiple myeloma and heavily pre-treated patients with hematological and non-hematological malignancies. Transfus Apher Sci. 2019; 58(3): 318-322.-DOI: https://doi.org/10.1016/j.transci.2019.03.018.

Giebel S., Kruzel T., Czerw T., et al. Intermediate-dose Ara-C plus G-CSF for stem cell mobilization in patients with lymphoid malignancies, including predicted poor mobilizers. Bone Marrow Transplant. 2013; 48(7): 915-921.-DOI: https://doi.org/10.1038/bmt.2012.269.

Calderón-Cabrera C., Carmona González M., Martín J. Intermediate doses of cytarabine plus granulocyte-colony-stimulating factor as an effective and safe regimen for hematopoietic stem cell collection in lymphoma patients with prior mobilization failure. Transfusion. 2015; 55(4): 875-879.-DOI: https://doi.org/10.1111/trf.12906.

Olivieri J., Attolico I., Nuccorini R., et al. Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score. Bone Marrow Transplantation. 2018; 53(4): 461-473.-DOI: https://doi.org/10.1038/s41409-017-0051-y.

Моталкина М.С., Кулева С.А., Алексеев С.М., et al. Пример успешной мобилизации стволовых кроветворных клеток периферической крови с помощью плериксафора и пэгфилграстима у пациентки с неходжкинской лимфомой. Современная онкология. 2015; 17(2): 54-56.-EDN: UHWCKX. [Motalkina M.S., Kulyova S.A., Alexeev S.M., et al. The illustration of the successful mobilization of hematopoietic stem cells using plerixafor and pegfilgrastim in the patient with non-Hodgkin's lymphoma. Journal of Modern Oncology. 2015; 17(2): 54-56.-EDN: UHWCKX. (In Rus)].

Кучер М.А., Моталкина М.С., Климова О.У., et al. Плериксафор у пациентов со сниженной мобилизационной способностью аутологичных гемопоэтических стволовых клеток. Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2016; 9(2): 155-161.- DOI: https://doi.org/10.21320/2500-2139-2016-9-2-155-161.-EDN: WEAVED. [Kucher M.A., Motalkina M.S., Klimova O.U., et al. Plerixafor in patients with decreased mobilizing ability of autologous hematopoietic stem cells. Clinical Oncohematology. 2016; 9(2): 155-161.-DOI: https://doi.org/10.21320/2500-2139-2016-9-2-155-161.-EDN: WEAVED. (in Rus)].

Моталкина М.С., Кулева С.А., Алексеев С.М., et al. Современные способы улучшения мобилизации стволовых кроветворных клеток: обзор литературы. Medline.ru. Российский биомедицинский журнал. 2015; 16: 916-933.-EDN: ZEUJDN. [Motalkina M.S., Kulyova S.A., Alexeev S.M., et al. New ways to improve the mobilization of hematopoietic stem cells: literature review. Medline.ru. Rossijskij Biomedicinskij Zhurnal. 2015; 16: 916-933. (in Rus)].

DiPersio J.F., Stadtmauer E.A., Nademanee A., et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009; 113(23): 5720-5726.-DOI: https://doi.org/10.1182/blood-2008-08-174946.

Stiff P., Micallef I., McCarthy P., et al. Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient. Biol Blood Marrow Transplant. 2009; 15(2): 249-256.-DOI: https://doi.org/10.1016/j.bbmt.2008.11.028.

Hübel K., Ostermann H., Glaß B., et al. Plerixafor in non-Hodgkin's lymphoma patients: a German analysis of time, effort and costs. Bone Marrow Transplant. 2019; 54(1): 123-129.-DOI: https://doi.org/10.1038/s41409-018-0228-z.

Mohty M., Azar N., Chabannon C., et al. Plerixafor in poor mobilizers with non-Hodgkin's lymphoma: a multi-center time-motion analysis. Bone Marrow Transplant. 2018; 53(3): 246-254.-DOI: https://doi.org/10.1038/s41409-017-0033-0.

Sung A.D., Grima D.T., Bernard L.M., et al. (2013). Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF alone. Bone Marrow Transplantation. 2013; 48(11): 1444-1449.-DOI: https://doi.org/10.1038/bmt.2013.80.

Sarici A., Erkurt M.A., Kuku I., et al. Selection of the mobilization regimen in lymphoma patients: A retrospective cohort study. Transfus Apher Sci. 2021; 60(5): 103251.-DOI: https://doi.org/10.1016/j.transci.2021.103251.

Wang L., Xiang H., Yan Y., et al. Comparison of the efficiency, safety, and survival outcomes in two stem cell mobilization regimens with cyclophosphamide plus G-CSF or G-CSF alone in multiple myeloma: a meta-analysis. Ann Hematol. 2021; 100: 563-573.-DOI: https://doi.org/10.1007/s00277-020-04376-w.

Czerw T., Sadus-Wojciechowska M., Michalak K., et al. Increased efficacy of stem cell chemomobilization with intermediate-dose cytarabine plus granulocyte colony-stimulating factor (G-CSF) compared with G-CSF alone in patients with multiple myeloma: results of a randomized trial. Biol Blood Marrow Transplant. 2019; 25(2): 248-255.-DOI: https://doi.org/10.1016/j.bbmt.2018.09.023

Luo C., Wu G., Huang X., et al. Efficacy of hematopoietic stem cell mobilization regimens in patients with hematological malignancies: a systematic review and network meta-analysis of randomized controlled trials. Stem Cell Res Ther. 2022; 13: 123.-DOI: https://doi.org/10.1186/s13287-022-02802-6.

Kruzel T., Sadus-Wojciechowska M., Najda J., et al. Very high efficacy of intermediate-dose cytarabine in combination with G-CSF as a second-line mobilization of hematopoietic stem cells. Int J Hematol. 2012; 96(2): 287-289.-DOI: https://doi.org/10.1007/s12185-012-1135-5.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Most read articles by the same author(s)

Sheyda R. Abdullaeva, Tatiana Yu. Semiglazova, Anna S. Artemyeva, Valentina A. Zagoruiko, Tatiana I. Kudriashova, Olga I. Ponasenko, Boris S. Kasparov, Larisa V. Filatova, Vladislav V. Semiglazov, Petr V. Krivorotko, Vladimir F. Semiglazov, Predictive and Prognostic Role of TILs In Platinum-Based Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer , Voprosy onkologii : Vol. 70 No. 3 (2024)
Stanislav A. Volchenkov, Larisa V. Filatova, Илья Сергеевич Зюзгин, Irina V. Ishmatova, Anna A. Zverkova, Margarita S. Motalkina, Julia A. Julia A. Nikulina, Eugenia V. Dobrovolskaya , Svetlana S. Elkhova, Alexei K. Koviazin, Leonid A. Kramynin, Nikita S. Kolupaev, Asel A. Isimbaeva, Tatiana Semiglazova, The Role of Nutritional Support on the Recovery of Patients with Hodgkin's Lymphoma during High-Dose Chemotherapy with Autologous Stem Cell Transplantation , Voprosy onkologii : Vol. 69 No. 4 (2023)